LABORATOIRES EUROMEDIS (ALEMG.PA) Fundamental Analysis & Valuation

EPA:ALEMG • FR0000075343

Current stock price

4.68 EUR
+0.04 (+0.86%)
Last:

This ALEMG.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALEMG.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALEMG has reported negative net income.
  • The reported net income has been mixed in the past 5 years: ALEMG reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: ALEMG reported negative operating cash flow in multiple years.
ALEMG.PA Yearly Net Income VS EBIT VS OCF VS FCFALEMG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

  • With a Return On Assets value of -13.77%, ALEMG is not doing good in the industry: 72.41% of the companies in the same industry are doing better.
  • ALEMG has a worse Return On Equity (-33.03%) than 68.97% of its industry peers.
Industry RankSector Rank
ROA -13.77%
ROE -33.03%
ROIC N/A
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ALEMG.PA Yearly ROA, ROE, ROICALEMG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • ALEMG has a worse Gross Margin (26.77%) than 84.48% of its industry peers.
  • In the last couple of years the Gross Margin of ALEMG has remained more or less at the same level.
  • ALEMG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
ALEMG.PA Yearly Profit, Operating, Gross MarginsALEMG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ALEMG.PA Health Analysis

2.1 Basic Checks

  • ALEMG has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ALEMG has been reduced compared to 5 years ago.
  • Compared to 1 year ago, ALEMG has an improved debt to assets ratio.
ALEMG.PA Yearly Shares OutstandingALEMG.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ALEMG.PA Yearly Total Debt VS Total AssetsALEMG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • ALEMG has an Altman-Z score of 1.89. This is not the best score and indicates that ALEMG is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of ALEMG (1.89) is worse than 60.34% of its industry peers.
  • ALEMG has a Debt/Equity ratio of 0.52. This is a neutral value indicating ALEMG is somewhat dependend on debt financing.
  • The Debt to Equity ratio of ALEMG (0.52) is worse than 62.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z 1.89
ROIC/WACCN/A
WACCN/A
ALEMG.PA Yearly LT Debt VS Equity VS FCFALEMG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

  • ALEMG has a Current Ratio of 3.07. This indicates that ALEMG is financially healthy and has no problem in meeting its short term obligations.
  • ALEMG has a better Current ratio (3.07) than 81.03% of its industry peers.
  • A Quick Ratio of 2.25 indicates that ALEMG has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 2.25, ALEMG belongs to the best of the industry, outperforming 82.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.07
Quick Ratio 2.25
ALEMG.PA Yearly Current Assets VS Current LiabilitesALEMG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ALEMG.PA Growth Analysis

3.1 Past

  • The earnings per share for ALEMG have decreased strongly by -144.11% in the last year.
  • Looking at the last year, ALEMG shows a very negative growth in Revenue. The Revenue has decreased by -26.59% in the last year.
  • ALEMG shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -14.02% yearly.
EPS 1Y (TTM)-144.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.64%
Revenue 1Y (TTM)-26.59%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%11.95%

3.2 Future

  • ALEMG is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.07% yearly.
  • The Revenue is expected to decrease by -18.80% on average over the next years. This is quite bad
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALEMG.PA Yearly Revenue VS EstimatesALEMG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
ALEMG.PA Yearly EPS VS EstimatesALEMG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

3

4. ALEMG.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALEMG. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 9.91, which indicates a very decent valuation of ALEMG.
  • Based on the Price/Forward Earnings ratio, ALEMG is valued cheaply inside the industry as 89.66% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of ALEMG to the average of the S&P500 Index (21.36), we can say ALEMG is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.91
ALEMG.PA Price Earnings VS Forward Price EarningsALEMG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALEMG.PA Per share dataALEMG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • ALEMG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.07%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALEMG.PA Dividend Analysis

5.1 Amount

  • No dividends for ALEMG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALEMG.PA Fundamentals: All Metrics, Ratios and Statistics

LABORATOIRES EUROMEDIS

EPA:ALEMG (4/30/2026, 7:00:00 PM)

4.68

+0.04 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength38.51
Industry Growth70
Earnings (Last)04-23
Earnings (Next)N/A
Inst Owners2.03%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.43M
Revenue(TTM)38.40M
Net Income(TTM)-5.48M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.91
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.81
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)0.47
Fwd EY10.09%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS13.38
BVpS5.78
TBVpS5.76
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -13.77%
ROE -33.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.77%
FCFM N/A
ROA(3y)0.89%
ROA(5y)6.05%
ROE(3y)1.29%
ROE(5y)13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.6%
GM growth 5Y1.2%
F-ScoreN/A
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.07
Quick Ratio 2.25
Altman-Z 1.89
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-144.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.64%
EPS Next Y8.35%
EPS Next 2Y7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.59%
Revenue growth 3Y-31.34%
Revenue growth 5Y-14.02%
Sales Q2Q%11.95%
Revenue Next Year7.54%
Revenue Next 2Y-18.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y68.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

LABORATOIRES EUROMEDIS / ALEMG.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LABORATOIRES EUROMEDIS (ALEMG.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALEMG.PA.


Can you provide the valuation status for LABORATOIRES EUROMEDIS?

ChartMill assigns a valuation rating of 3 / 10 to LABORATOIRES EUROMEDIS (ALEMG.PA). This can be considered as Overvalued.


How profitable is LABORATOIRES EUROMEDIS (ALEMG.PA) stock?

LABORATOIRES EUROMEDIS (ALEMG.PA) has a profitability rating of 1 / 10.


How financially healthy is LABORATOIRES EUROMEDIS?

The financial health rating of LABORATOIRES EUROMEDIS (ALEMG.PA) is 5 / 10.